🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Asrar Alahmadi

State Library of Ohio

ORCID: 0000-0001-7385-2843

Also affiliated with The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.104Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004
Top 78%
0.104DataRank
Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

Papers

Driven by 7 papers — median percentile 22. Top paper: “Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors”.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors

Cancer Investigation(2025)10.1080/07357907.2025.2557004
Top 78%
0.104DataRank
Top 78%1 citations

Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain, Daniel Spakowicz +15 more

Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03392-9
N/A
0DataRank · unranked
11 citations

Songzhu Zhao, Gabrielle Lopez, Austin Secor, Parthib Das, Nitya Surya +19 more

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e21094
N/A
0DataRank · unranked
0 citations

Songzhu Zhao, Kenneth Chian, Hyunwoo Kwon, Nicholas Jones, Adam Khorasanchi +15 more

Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0365
N/A
0DataRank · unranked
23 citations

Ashley M. Shay, Karen McColl, Suzy Yoon, Mohammad A. Shatat, Ahmad Perwez +11 more

Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.07.002
N/A
0DataRank · unranked
0 citations

Philip Young, Songzhu Zhao, Lai Wei, Sandip H. Patel, Mingjia Li +17 more

Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non‐Small‐Cell Lung Cancer Treated With Front‐Line Immunotherapy‐Based Therapies

Cancer Medicine(2025)10.1002/cam4.71058
N/A
0DataRank · unranked
0 citations

Po‐Lan Su, Songzhu Zhao, Grace Cheng, Nicholas Jones, Kenneth Chian +26 more

Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy

Lung Cancer(2025)10.1016/j.lungcan.2025.108832
N/A
0DataRank · unranked
0 citations

Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn Goodyear, Kevin Ho +16 more